MedPath

A prospective cohort study to search for a risk factor of chemotherapy induced nausea and vomiting in patients with colorectal cancer.

Phase 4
Recruiting
Conditions
colorectal cancer
Registration Number
JPRN-UMIN000010165
Lead Sponsor
Yokohama City University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

1. The patient who experienced nausea or vomiting within 24 hours before giving an anticancer agent 2. Any other inadequacy for this study

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Complete response rate during 24 to 120 hours (delay phase) after an anticancer agent dosage start
Secondary Outcome Measures
NameTimeMethod
1. Complete response rate during 0 to 24 hours (acute phase) and 0 to 120 hours (all phase ) after an anticancer agent dosage start 2. Complete control rate during acute phase and delay phase and all phase after an anticancer agent dosage start 3. Grade of nausea during acute phase and delay phase and all phase after an anticancer agent dosage start
© Copyright 2025. All Rights Reserved by MedPath